Workflow
Twist Bioscience(TWST)
icon
Search documents
Twist Bioscience(TWST) - 2023 Q4 - Earnings Call Transcript
2023-11-17 16:52
Financial Data and Key Metrics Changes - Revenue for Q4 2023 grew to $66.9 million, bringing total revenue for fiscal year 2023 to $245.1 million, representing a year-over-year growth of approximately 20% [9][64] - Gross margin for both the quarter and the year was approximately 37% [9][49] - Cash, cash equivalents, and investments at the end of the year totaled approximately $336 million [9][42] Business Line Data and Key Metrics Changes - NGS revenue for Q4 increased to approximately $37.1 million, a 27% year-over-year growth, with full-year revenue reaching $123.7 million, up 25% from the previous year [36] - SynBio revenue for Q4 was $26.5 million, totaling $98.2 million for fiscal 2023, up from $80 million in fiscal 2022 [37] - Biopharma revenue for Q4 was $3.4 million, totaling $23.2 million for fiscal 2023, a decline from $24.2 million in fiscal 2022 [38] Market Data and Key Metrics Changes - EMEA revenue rose to $71.4 million compared to $62.1 million in fiscal 2022, while APAC revenue increased to $22.5 million from $19.1 million [39] - U.S. revenue increased to $151.3 million in fiscal 2023 from $122.5 million in fiscal 2022 [39] Company Strategy and Development Direction - The company is focused on profitable and stable growth moving into fiscal 2024, with strategic actions aimed at optimizing operations and increasing gross margins [26][74] - The launch of Express Genes is expected to enhance contribution margins and expand market opportunities [56][58] - The company aims to leverage its investments in the Wilsonville facility to drive future growth and profitability [27][74] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery in Biopharma revenue, indicating that Q4 2023 may represent the low point for this segment [32] - The company is focused on scaling Express Genes and managing costs while continuing to grow revenue and expand gross margins [74][90] - Management acknowledged macroeconomic challenges but emphasized the differentiated product offerings that position the company favorably in the market [119][120] Other Important Information - The company ended fiscal 2023 with approximately $336 million in cash and investments, down from $39 million in inventory at the end of fiscal 2022 [42][64] - Operating expenses for fiscal 2023 decreased to approximately $306.8 million from $319 million in fiscal 2022 [40] Q&A Session Summary Question: Can you talk about how much of the guidance implies or bakes in the Fast Genes? - Management indicated that the guidance reflects expectations for Express Genes and its impact on margins [51] Question: What feedback are you getting for Express Genes? - Management noted positive feedback from a mix of large pharma, small pharma, and academic customers, with a focus on existing customers for initial uptake [53][55] Question: Can you provide insight on the current penetration of the makers market? - The company estimates the makers market to be a $1.4 billion opportunity, with current penetration being minimal but with significant potential for growth through Express Genes [85] Question: What are the expectations for data storage spending in fiscal 2024? - Data storage operating expenses are expected to be in the range of $37 million to $39 million for the year [123] Question: How should we think about adjusted EBITDA loss for Biopharma for the year? - Management indicated that the focus is on achieving adjusted EBITDA breakeven for Biopharma, NGS, and SynBio as quickly as possible [124]
Twist Bioscience(TWST) - 2023 Q3 - Quarterly Report
2023-08-06 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...
Twist Bioscience(TWST) - 2023 Q3 - Earnings Call Transcript
2023-08-04 22:24
Twist Bioscience Corporation (NASDAQ:TWST) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust - CEO and Co-Founder Jim Thorburn - CFO Conference Call Participants Vijay Kumar - Evercore ISI Matt Sykes - Goldman Sachs Puneet Souda - Leerink Partners Luke Sergott - Barclays Steven Mah - TD Cowen Catherine Schulte - Baird Rachel Vatnsdal - JP Morgan Matt Larew - William Blair Sung-Ji Nam - Scotiabank Operator ...
Twist Bioscience(TWST) - 2023 Q3 - Earnings Call Presentation
2023-08-04 12:05
ACTACCATCAT Financial Results . BIOSCIENCE Welcome Angela Bitting SVP, Corporate Affairs; Chief ESG Officer Financial and Operational Performance Jim Thorburn Chief Financial Officer Q&A Session T This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act o ...
Twist Bioscience(TWST) - 2023 Q2 - Quarterly Report
2023-05-07 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...
Twist Bioscience(TWST) - 2023 Q2 - Earnings Call Transcript
2023-05-05 16:31
Twist Bioscience Corporation (NASDAQ:TWST) Q2 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and ESG Officer Emily Leproust - CEO and Co-Founder James Thorburn - CFO Conference Call Participants Vijay Kumar - Evercore ISI Matt Larew - William Blair Steven Mah - Cowen Sung-Ji Nam - Scotiabank Luke Sergott - Barclays Puneet Souda - SVB Securities Tom Peterson - Baird Rachel Vatnsdal - JPMorgan Operator Good morning, ladies and gentlemen, and w ...
Twist Bioscience(TWST) - 2023 Q1 - Quarterly Report
2023-02-06 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 (State or other jurisdict ...
Twist Bioscience(TWST) - 2023 Q1 - Earnings Call Transcript
2023-02-03 19:10
Twist Bioscience Corp (NASDAQ:TWST) Q1 2023 Earnings Conference Call February 3, 2023 8:00 AM ET Company Participants Angela Bitting - Chief ESG Officer & SVP, Corporate Affairs Emily Leproust - Co-Founder, Chairman & CEO James Thorburn - CFO Conference Call Participants Poon Mah - Cowen and Company Luke Sergott - Barclays Bank Matthew Larew - William Blair & Company Vijay Kumar - Evercore ISI Puneet Souda - SVB Securities Noah Burhance - JPMorgan Chase & Co. Operator Welcome to Twist Bioscience's Fiscal 20 ...
Twist Bioscience(TWST) - 2022 Q4 - Annual Report
2022-11-27 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...
Twist Bioscience(TWST) - 2022 Q4 - Earnings Call Transcript
2022-11-18 15:18
Twist Bioscience Corporation (NASDAQ:TWST) Q4 2022 Earnings Conference Call November 18, 2022 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs & Chief ESG Officer Emily Leproust - Chief Executive Officer & Co-Founder Jim Thorburn - Chief Financial Officer Conference Call Participants Steven Mah - Cowen Catherine Schulte - RW. Baird Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Vijay Kumar - Evercore ISI Puneet Souda - SVB Securities Rachel Vatnsdal - JPMor ...